Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
05/10/2012 | 01:16am CEST

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
08/18 MERCK AND : AstraZeneca and Merck & Co., Inc. - LYNPARZA Receives Additional and..
08/18 ASTRAZENECA : and Merck & Co., Inc. - LYNPARZA receives additional FDA approval ..
08/18DJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 ASTRAZENECA : LYNPARZA® (olaparib) Receives Additional FDA Approval in the US fo..
08/17 ASTRAZENECA : Lynparza receives additional and broad approval in the US for ovar..
08/14 Big-name U.S. hedge funds shed healthcare stocks during the rally in second-q..
08/14 Big-name U.S. hedge funds shed healthcare stocks during the rally in second q..
08/11 PFIZER : attempting to develop therapies for pancreatic cancer have failed
08/11 PIERIS PHARMACEUTICALS : Reports Financial Results for the Second Quarter Ended ..
More news
News from SeekingAlpha
08/18 Surprisingly Broad Lynparza Approval Levels The Playing Field
08/18 AstraZeneca, Time To Expand The Operation
08/17 FDA OKs expanded use for AstraZeneca's Lynparza
08/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 17, 2017
08/11 STARPHARMA : At Last It Is Happening
Financials ($)
Sales 2017 21 584 M
EBIT 2017 5 714 M
Net income 2017 2 629 M
Debt 2017 12 527 M
Yield 2017 4,73%
P/E ratio 2017 26,03
P/E ratio 2018 22,06
EV / Sales 2017 3,97x
EV / Sales 2018 3,94x
Capitalization 73 101 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 62,9 $
Spread / Average Target 9,1%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA0.98%73 101
JOHNSON & JOHNSON15.48%357 079
ROCHE HOLDING LTD.5.37%218 752
NOVARTIS10.59%218 545
PFIZER1.45%196 221